— FDA approval would allow widespread access for U.S. patients with Duchenne —
— Deflazacort could be among the first FDA-approved treatments for this devastating genetic disorder —
Raising awareness about how muscular dystrophy, ALS and related muscle-debilitating diseases impact the families we serve is critical for educating people about the urgent need for action and support.
Vice President of Public Relations
3300 E. Sunrise Drive, Tucson, AZ 85718
(520) 529-5305 telephone; (520) 529-5353 fax
MDA is here to provide assistance with local or national stories about MDA, our lifesaving research and treatments, family stories/interviews, treatment protocols, expert perspectives on diseases in MDA's program, fundraising events, corporate partnerships and other issues related to muscular dystrophy, ALS and related muscle-debilitating diseaes. Call our public relations department at (520) 529-5317 or email email@example.com for assistance.